Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction

• Published in: Terapevtic̆eskii arhiv Vol. 79; no. 4; p. 49
• Main Authors: Chelysheva, E Iu, Turkina, A G, Misiurin, A V, Aksenova, E V, Domracheva, E V, Zakharova, A V, Khoroshko, N D
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2007
• Subjects: Adult; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Benzamides; beta 2-Microglobulin - blood; beta 2-Microglobulin - genetics; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Bone Marrow - pathology; Female; Fusion Proteins, bcr-abl - blood; Fusion Proteins, bcr-abl - genetics; Gene Expression Regulation, Leukemic - drug effects; Genes, abl - genetics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Neoplasm, Residual; Piperazines - administration & dosage; Piperazines - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Neoplasm - genetics; Sensitivity and Specificity

To quantitatively determine minimal residual disease (MRD) by real-time polymerase chain reaction (PCR) in patients with a chronic phase (CP) of chronic myeloid leukemia (CML). A molecular response was analyzed in 53 CML CP patients with incomplete and complete cptogenetic response (ICR and CCR) dur...